General Research
Model: human
Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson’s disease: a pilot study
Simplified Version Available
Breathing New Hope: Hydrogen Inhalation for Parkinson's Disease
A pilot study in Japan found that inhaling hydrogen gas improved movement and cognitive function in people with Parkinson's disease. The treatment reduced oxidative stress and inflammation in the brain, offering new hope for managing symptoms and slowing disease progression. While more research is needed, hydrogen inhalation could become a valuable tool in the fight against Parkinson's.
Read Simplified ArticleAbstract
Publish Year 2021 Country Japan Rank Neutral Journal Neurological Sciences Primary Topic Brain Secondary TopicParkinson's Disease Model Human Tertiary TopicNeurodegeneration Vehicle Gas pH N/A Application Inhalation Comparison Complement Levodopa
Background
Methods: Twenty participants fulfilling the Movement Disorder Society criteria were enrolled. Participants inhaled 6.5 (0.1) vol% hydrogen gas in 2 L/min of mixed air or placebo air for 16 weeks, twice a day for 1 h.
Methods
Results: Five participants were excluded due to deviation from the protocol of the total duration of inhalation 0.05). No adverse events were seen. The compliance to the protocol-based duration of inhalation time in all participants decreased with the elderly participants, the higher daily dose of levodopa, and the higher PDQ-39 items on emotions (n = 20, p < 0.05).
Results
Conclusion: This pilot study revealed that the inhalation of molecular hydrogen gas was safe, but did not show any beneficial effects in patients with PD. Trial registration: UMIN ID: 000,039,217 (October 6, 2018).